Inhibiting the Enzyme G6PD Destroys Metastatic Ovarian Cancer Cells in the Omentum

A team from the Los Angeles-based Terasaki Institute for Biomedical Innovation has identified the key role of a metabolic enzyme in ovarian cancer metastasis. The enzyme, glucose-6-phosphate dehydrogenase (G6PD), promotes cancer growth and metastasis development in the omentum, a plica of fatty tissue located in the abdominal cavity. These new data, presented in Cell Reports, also confirm the role of fatty acids as fuel for tumors.

Read Also: Trans Fatty Acids Promote Ovarian Cancer According to Study

Ovarian Cancer

Ovarian Cancer seen on CT. Credit: James Heilman, MD

Ovarian cancer cells aggressively migrate and proliferate in this epiploic fold of fat, metabolizing fatty acids and using them as fuel. In this process, and through the identified G6PD pathway, harmful oxidative compounds accumulate, further promoting cancer cell growth.

G6PD, a key enzyme, a promising therapeutic target

By identifying this role of G6PD, the study helps explain the rapid progression of ovarian cancer, a particularly lethal metastatic disease in which 80 percent of patients are diagnosed at stage III or higher. The prognosis of this cancer is therefore very poor, with a 5-year survival rate of about 30 percent. Aggressive migration and spread of tumor cells in the omentum is well documented and with good reason, as this adipose tissue provides the tumor with fatty acids as a fuel source.

Read Also: Adagrasib a Promising New Treatment for Lung, Pancreatic, Endometrial, Ovarian, and Colon Cancers

The study

Genetic and metabolic analyses revealed that this increase in fatty acid metabolism of tumor cells induces the production of oxidative compounds, which increase the level of oxidative stress in the tumor microenvironment and impair tumor cell metabolism. G6PD counteracts the effects of this oxidative stress and promotes metabolism and thus metastasis in the omentum.

Therefore, elevated levels of oxidative compounds and metabolites are observed in omentum metastases compared with primary tumors. Similar observations have been made in mouse models of ovarian cancer and in tumor cell lines and organoids cultured with omental tissue.

When researchers inhibit G6PD through gene silencing or pharmacological inhibition, they observe tumor cell death, particularly in media conditioned to be “epiploic.” These results suggest that G6PD expression is necessary for tumor development and metastasis. The same result was obtained in mouse models of ovarian cancer: the mice treated with a G6PD inhibitor drug developed fewer metastatic tumors in the omentum.

Read Also: Scientists Develop Lipid Nanoparticles That Can Transport Drugs Past Tumor Defenses

Final Thoughts

G6PD is an important component that compensates for the oxidative stress created by fatty acid metabolism by cancer cells in the omentum. Without this enzyme, metastatic cells die due to oxidative stress. This new understanding of the metabolic process that influences tumor survival, growth, and metastasis reveals a new therapeutic target for this poor prognosis cancer.


G6PD inhibition sensitizes ovarian cancer cells to oxidative stress in the metastatic omental microenvironment



Want to Stay Informed?

Join the Gilmore Health News Newsletter!

Want to live your best life?

Get the Gilmore Health Weekly newsletter for health tips, wellness updates and more.

By clicking "Subscribe," I agree to the Gilmore Health and . I also agree to receive emails from Gilmore Health and I understand that I may opt out of Gilmore Health subscriptions at any time.